Recon: FDA rejects J&J’s application for injectable lung cancer drug; BD to pay $175M to settle SEC Alaris pump charges
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited StatesUS Food and Drug Administration (FDA)